

CITATION REPORT

List of articles citing

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

DOI: 10.1002/cncr.33095
Cancer, 2020, 126, 4390-4399.

Source: <https://exaly.com/paper-pdf/75836755/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
13	Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. <i>BMJ, The</i> , 2020 , 371, m3434	5.9	22
12	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 527-540	2.2	11
11	Innovation in breakthrough drugs and vaccines: Development risk, patient impact, and value. <i>Drug Discovery Today</i> , 2021 , 26, 2232-2237	8.8	2
10	The value of new drugs for advanced prostate cancer. <i>Cancer</i> , 2021 , 127, 3457-3465	6.4	0
9	An urgent call to raise the bar in oncology. <i>British Journal of Cancer</i> , 2021 , 125, 1477-1485	8.7	5
8	Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. <i>JCO Oncology Practice</i> ,	2.3	2
7	Association between control group therapy and magnitude of clinical benefit of cancer drugs..		
6	A cross-sectional study of the FDA approved indications and supporting pivotal trials of small-molecular kinase inhibitors in cancer therapies with the biomarker of cancer driver gene.		0
5	Association between control group therapy and magnitude of clinical benefit of cancer drugs. 2022 , 12,		0
4	When are breakthrough therapies cost-effective?. 2022 , 28, 732-739		1
3	Reply to E. Noguchi et al.		0
2	Introduction of managed entry agreements in Korea: Problem, policy, and politics. 14,		0
1	Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020. 11,		0